1. Introduction
Non-small cell lung cancer (NSCLC) continues to carry a poor prognosis despite advances in treatment options [1]. Even with complete resection, the recurrence rate remains substantial [2,3,4]. The mechanism behind postoperative recurrence is thought to be as follows: microscopic cancer cells may already be circulating in the bloodstream at the time of complete resection, undetectable through imaging. Recurrence occurs when these cells lodge in major organs, such as the brain or liver, forming new tumor masses. These microscopic tumor cells, known as circulating tumor cells (CTCs), have been shown to correlate with poor prognosis across various cancers [5,6].
CTCs in the bloodstream are attracting attention as a biomarker for predicting cancer treatment effects and prognosis in various cancers. In NSCLC, past reports demonstrated that CTCs are useful for diagnosing lung cancer and predicting treatment effects [7,8,9,10,11]. These past studies investigated the presence or absence of CTCs in the bloodstream morphologically. The problem was that the detection rate of CTCs was low. This method mainly counts single cells using EpCAM, an antigen specific to epithelial cells, as an indicator, and its low sensitivity in the peripheral bloodstream was an issue that needed improvement. Past studies of CTCs mainly targeted pulmonary venous blood in lung cancer surgery cases [12,13]. As one way to solve this problem, we previously showed the impact of CTCs in peripheral bloodstream using ScreenCell® [14].
We hypothesized that surgical manipulation could release CTCs from the NSCLC tumor into the bloodstream, potentially playing a significant role in recurrence. Based on this hypothesis, we previously conducted a multicenter study to examine the impact of surgical manipulation on CTC levels in NSCLC patients (UMIN000018602) [15]. In that study, pre-CTCs were present prior to surgical manipulation in 13 of 29 cases, with all these cases also showing post-CTCs. Among the remaining 16 cases without pre-CTCs, post-CTCs appeared after surgical manipulation in four cases. These findings suggested that surgical intervention may induce CTC release. After a 5-year follow-up, we report on the prognosis and recurrence status. This prospective study is the first to assess the prognostic impact of CTCs in this context.
2. Materials and Methods
2.1. Study Design
This multicenter prospective controlled study was approved by the Institutional Ethics Review Board (Teikyo University Review Board 15-010) and registered with the University Hospital Medical Information Network (UMIN000018602). All participants pro-vided written informed consent before study entry. Since no studies have been conducted on pre- and post-CTCs, a statistical prediction was not possible. Pre-CTCs were defined as CTCs which were detected in the blood sample from the radial artery before surgery. Post-CTCs were defined as CTCs which were collected in the blood sample after pulmonary vein dissection. Therefore, the study was considered evidence-generating with no hypotheses, and the number of patients was tentatively set. For a multicenter study, the number of patients enrolled annually was predicted to be 30. Institutions with at least 50 annual cases of curative surgery for primary lung cancer were invited to participate, and each institution was instructed to enroll a minimum of four patients to minimize technical variability of the ScreenCell® between institutions. The primary endpoint of this study was the detection frequency of CTCs in the blood by the ScreenCell® method. The secondary endpoints were the relationships between CTCs and pathological factors and CTCs and surgical manipulation. A concomitant retrospective study was the prognostic impact of CTCs.
2.2. Inclusion and Exclusion Criteria
In this study, patients who had been diagnosed with NSCLC by preoperative histological or cytological biopsy or by intraoperative rapid cytological or histological biopsy after lobectomy were enrolled. The stage of all patients was determined according to the 7th edition of the TNM classification of lung and pleural tumors. The study was designed for patients with cT1b-2 (2–7 cm) N0M0 NSCLC scheduled to undergo lobectomy. Eligible patients were between 20 and 80 years old, with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1, a proportion of consolidation to ground-glass opacity of over 50% on preoperative high-resolution computed tomography (CT), and patients who could tolerate lobectomy or higher based on preoperative respiratory function following two points: (i) predicted postoperative volume per second (FEV1.0) ≧ 800 mL and (ii) partial pressure of arterial oxygen (PaO2) ≧ 65 torr or arterial oxygen saturation (SaO2) > 90% (room air). Laboratory test results obtained within 14 days prior to enrollment had to meet all of the following criteria: (i) white blood cells (WBCs) ≥ 3000/mm3, ≤12,000/mm3; (ii) hemoglobin (Hb) ≥ 9.0 g/dL; (iii) platelet count ≥ 10 × 104/mm3; (iv) aspartate aminotransferase (AST) ≤ 100 IU/L and alanine aminotransferase (ALT) ≤ 100 IU/L; (v) total bilirubin ≤ 1.5 mg/dL; and (vi) serum creatinine ≤ 1.5 mg/dL. Patients receiving corticosteroids or immunosuppressive drugs and those with severe disease (uncontrolled heart, lung, liver, or kidney disease or diabetes), synchronous or metachronous malignancies, or preoperative anticancer therapy were excluded from the study. Also, we excluded patients with active infections, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) infections. Patients were excluded from this study if blood sampling was difficult for some reason, or even if the planned surgical procedure changed.
2.3. Blood Sampling
Blood samples for CTC testing were collected from a catheter inserted into the radial artery to monitor blood pressure during surgery, ensuring no additional invasive procedures were required for this study. Blood samples for pre-CTCs were collected before surgical operation in supine position. After confirming unresectable factors, including malignant pleural effusion or disseminated lesions, lobectomy with mediastinal lymph node dissection was performed by a thoracic surgeon under general anesthesia. Minimally invasive surgery (thoracoscopic surgery or thoracotomy with less than 8 cm skin incision) was performed according to procedures developed at each institution. The surgical approach was determined by surgeons based on the location and size of the tumor. In the operating room, a 22 or 20 G catheter was inserted into the radial artery under general anesthesia, and at least 3 mL of blood sample was collected in an EDTA-2Na-containing tube before surgery (for pre-CTCs measurement) and immediately after pulmonary vein (PV) dissection (for post-CTCs measurement). CTCs were extracted by the size-selective method using ScreenCell® (ScreenCell CYTO R kit produced by SCREEN Holdings Co., Kyoto, Japan) using a 3 mL blood sample within 4 h of blood collection. The specimens were H&E-stained and prepared on glass slides with cover glass for microscopic analysis at each institution. The glass slides were stored in protective containers and transferred to the main research center. Three pathologists examined the glass slides blindly for the presence or absence of cancer cells (positive or negative). Cancer cells were confirmed by cytological examination, not by markers. The presence of even one cancer cell was considered as “positive”. Consistency of diagnosis by two of the three pathologists was used. All circulating cancer cells found were photographed with a digital camera and stored. The images of circulating cancer cells taken were sent to the principal investigator for confirmation. The presence or absence of circulating cancer cells were recorded using images taken with the digital camera and stored. Details on the diagnosis regarding the presence of CTCs are provided in our previous report [14].
2.4. Follow-Up Method
After surgery, a minimum follow-up period of 5 years was established at each institution. Chest X-ray was performed every 6 months. A chest CT scan was conducted every 6 months for the first two years post-surgery, followed by annual scans thereafter. Additional imaging, such as CT, magnetic resonance imaging (MRI), and/or positron emission tomography–computed tomography (PET-CT), was conducted depending on the patient’s symptoms. Pulmonary metastasis was a nodular shadow detected in the remaining lung. Differentiation from metachronous multiple lung cancer was based on the clinical course and the characteristics of the shadow, such as an increase in tumor markers. A definitive histological diagnosis was not made in all cases. Local recurrence was defined as recurrence in the ipsilateral lung, contralateral lung, bronchial stump, pleural dissemination, malignant pleural effusion, hilar lymph nodes, or mediastinal lymph nodes. All other recurrences were classified as distant recurrences.
2.5. Statistical Analysis
For the statistical analysis, the IBM® SPSS Statistics version 26.0 (IBM, Armonk, NY, USA) software package was used. All p-values were two-sided, and p-values less than 0.05 were considered to represent statistically significant differences. Fisher’s exact test was used to analyze categorical variables, and Student’s t-test was used to analyze continuous variables. Survival curves were plotted using the Kaplan–Meier method, and log-rank tests were used to compare survival times. The zero time was the date of pulmonary resection. The endpoint of overall survival (OS) was defined as the date of death from any cause, and the last follow-up observation was censored when the patient was alive or lost to follow-up. The endpoint of recurrence-free survival (RFS) was defined as the date when recurrence was confirmed, or the date of death from any cause, and the last follow-up observation was censored when the patient was alive without recurrence or lost to follow-up.
3. Results
As previously reported, 31 patients from six centers were enrolled between July 2015 and January 2016. Two patients were excluded from the study due to the discovery of pleural dissemination during surgery, resulting in 29 patients included in the study. All patients were followed-up with for more than 5 years after surgery at each institution, with a median follow-up period of 5.1 years.
3.1. Patient Characteristics
The patients’ characteristics are summarized in Table 1. Pre-CTCs positivity was significantly more frequent in patients with pathological stage II or higher disease and those with pleural invasion. No other clinicopathological factors were significantly associated with pre-CTCs. Post-CTCs positivity was observed significantly more often in patients with pathological stage II or higher disease. No other clinicopathological factors were significantly associated with post-CTCs.
3.2. Detection of CTCs Before and After Pulmonary Vein Dissection
A cross table shows pre-/post-CTCs presence in Table 2. Pre-CTCs positivity and negative were detected in 13 and 0 patients, respectively. Post-CTCs positivity and negative were observed in 17 and 12 patients, respectively.
3.3. Postoperative Survival
The 5-year recurrence-free survival rates for the patients without or with pre-CTCs were 80.2% and 46.2%, respectively (p = 0.066; Figure 1A). The median recurrence-free survival term was 52.7 months in the pre-CTCs-positive group, and was not reached in the post-CTCs-negative group. The 5-year recurrence-free survival rates for patients with post-CTCs were significantly inferior to those in patients without (p = 0.013), at 90.0% and 47.1%, respectively (Figure 1B). The median recurrence-free survival term was 52.7 months in the post-CTCs-positive group, and not reached in post-CTCs-negative group.
3.4. Difference in Recurrence
After 5 years of follow-up, 9 of the 29 cases (31.0%) developed a postoperative recurrence. Patients without pre-CTCs developed a recurrence in 3 of 16 cases (18.8%), whereas patients with pre-CTCs developed a recurrence in 6 of 13 cases (46.2%). Although patients with pre-CTCs had a higher recurrence rate than those without, the difference was not statistically significant (p = 0.226). For post-CTCs, patients without post-CTCs developed a recurrence in 1 of 12 cases (8.3%), whereas patients with post-CTCs developed a recurrence in 8 of 17 cases (47.1%), with the latter showing a significantly higher recurrence rate (p = 0.043). There were 4 of 29 cases without pre-CTCs but with post-CTCs, of which 2 cases (50.0%) experienced a recurrence.
Regarding local recurrence, 2 of 16 cases (12.5%) without pre-CTCs and 2 of 13 cases (15.3%) with pre-CTCs developed local recurrence (Table 3). Patients with pre-CTCs had a similar local recurrence rate than those without (p = 1.0). For post-CTCs, local recurrence occurred in 1 of 12 cases (8.3%) without post-CTCs and in 3 of 17 cases (17.6%) with post-CTCs, but this difference was also not statistically significant (p = 0.622).
For distant recurrence, 2 of 16 cases (12.5%) without pre-CTCs and 7 of 13 cases (53.8%) with pre-CTCs developed a distant recurrence (Table 4). Patients with pre-CTCs had a significantly higher distant recurrence rate than those without (p = 0.041). In the case of post-CTCs, distant recurrence occurred in 1 of 12 cases (8.3%) without post-CTCs and in 8 of 17 cases (47.1%) with post-CTCs, showing a higher rate among those with post-CTCs, and this difference was also significant (p = 0.043). The details of recurrence sites are presented in Table 5, but no distinct relationship was observed between CTC status and recurrence site.
3.5. CTCs Induced by Surgical Manipulation
Four cases (25%) without pre-CTCs changed in CTCs status after surgery, converting the post-CTCs status into positive (positive convert group). In these cases, two of the four cases (50%) developed a recurrence. One case developed a recurrence in the mediastinum lymph node, the other developed bone metastasis. The characteristics of the patients in the positive convert group are shown in Table 6. All four cases showed no lymph node metastasis and no pleural invasion.
The 5-year recurrence-free survival rates for the positive convert group and pre-/post-CTCs-negative patients were 50% and 90%, respectively (p = 0.050; Figure 2A). The 5-year recurrence-free survival rates for the positive convert patients and pre-/post-CTCs-positive patients were 50% and 46%, respectively (p = 0.70; Figure 2B). The median recurrence-free survival terms were 9.4 months in the positive convert group, 52.7 months in the pre-/post-CTCs-positive group, and not reached in pre-/post-CTCs-negative group, respectively. Except for one case that recurred in the distant period after 52 months, the two cases that recurred within 2 years were cases who showed positive conversion.
4. Discussion
In our previous report, the possibility of CTC dissemination into the bloodstream by surgical manipulation was demonstrated in cT1b-2N0M0 NSCLC patients (7). Among the 29 patients, 4 patients (13.8%) were considered to have post-CTCs positivity from a pre-CTCs-negative status, which could be induced intraoperatively by surgical technique. Hashimoto et al. investigated the relationship between surgery and CTCs by measuring CTC levels in blood drawn directly from the pulmonary vein before and after NSCLC surgery in 30 cases [15]. The median number of CTCs in the pulmonary vein increased significantly from 4 cells/2.5 mL before resection to 60 cells/2.5 mL after. Another study measured CTCs in peripheral blood taken before and after NSCLC surgery in 23 patients [16]. Among the 17 patients who did not have clustered pre-CTCs, 9 showed clustered post-CTCs in their peripheral blood. These findings, including our own, suggest that surgical manipulation for NSCLC may induce post-CTCs.
The presence of CTCs is a poor prognostic factor in various cancers [5,6] and has also been shown to predict a poor prognosis in lung cancer. Jin et al. reviewed studies on CTCs and prognosis in lung cancer, finding that CTC presence was significantly associated with worse prognoses in NSCLC (hazard ratio (HR) 2.11, 95% CI 1.63–2.73, p < 0.050) [17].
In our study, the pre-CTCs-positive rate was 44.9% and the post-CTCs-positive rate was 55.2%, a discrepancy which could suggest an intravascular influx of CTCs from the main tumor by surgical manipulation in 4 out of the 29 patients [12]. Although no statistically significant difference in OS in the pre-/post-CTCs groups was confirmed, the 5-year OS rate difference between patients with and without post-CTCs (100% vs. 76.5%) was equivalent to that observed with and without pre-CTCs (93.8% vs. 76.9%). And then, the CTCs-positive group showed poor OS in both pre- and post-CTCs (Appendix A). This finding suggests that CTC outflow may lead to poorer prognoses in NSCLC patients.
Pre-CTCs were not significantly associated with RFS (p = 0.066), but post-CTCs were significantly linked to poorer RFS (p = 0.013). Similarly to OS, the difference in the 5-year RFS rate between patients with and without post-CTCs (90.0% vs. 47.1%) was more significant than its difference between patients with and without pre-CTCs (80.2% vs. 46.2%), indicating that post-CTCs were associated with a poorer prognosis. Examining the site of recurrence, distant metastasis was significantly more frequent in cases that were positive for both pre-CTCs (p = 0.041) and post-CTCs (p = 0.043). In other words, this finding may suggest that post-CTC outflow strongly influences lung cancer recurrence. Here, we focus on patients who met the following conditions: pre-CTCs-negative and post-CTCs-positive (positive conversion group). In this group, it was highly possible that CTCs leaked from the tumor into the blood vessels due to surgeons’ manipulations. That could be why the RFS of the positive convert group was inferior to that of the pre-/post-CTCs-negative cases (p = 0.050). This result suggested that surgical manipulations have a possibility of worsening prognosis through CTCs.
Regarding the influx of cancer cells into the bloodstream due to surgical manipulations, Turnbull RB et al. reported in the 1960s that during colorectal cancer surgery, cancer cells may enter the bloodstream and cause recurrence [18]. Since this report, several studies on no-touch isolation techniques have been conducted, but no significant results have been obtained. Currently, prospective central vascular treatment is being investigated for colorectal cancer [19]. During surgery for NSCLC, primary tumors are subject to many physical influences, not only from the grasping and compressing the primary tumor during the operation, but also from the collapse and expansion of the lung due to separate lung ventilation, rapid needle biopsy, etc. Some have proposed that prior treatment of the pulmonary veins, which are the outflow tract, will prevent the release of cancer cells. But studies to date have not reached a clear conclusion [20]. Additionally, past reports suggested that surgical manipulations increase the levels of CTCs in pulmonary vein blood [13,21,22]. However, until now, the relationship between the increase in CTCs and prognosis was not clear [23,24,25]. We could prospectively examine prognosis for the first time. Examining the relationship between the increase in CTCs in the peripheral bloodstream and prognosis through intraoperative manipulation suggests the possibility of reducing metastasis and recurrence by devising improved surgical manipulations.
While surgically induced post-CTC outflow negatively impacted recurrence, OS was not significantly affected, likely due to advancements in NSCLC treatments, such as targeted therapies and immune checkpoint inhibitors, which may improve outcomes by controlling cancer progression after recurrence [26,27]. For recurrence rates, pre-CTCs did not show a significant difference (p = 0.266), whereas post-CTCs were significantly associated with increased recurrence rates (p = 0.043), supporting our hypothesis. Although we anticipated higher local and distant recurrence rates with post-CTC presence after surgical manipulation, this was not conclusively shown in this study.
This was a preliminary study with only 29 cases, and there were considerable limitations. In the near future, large-scale clinical trials enrolling more patients are needed in order to prove that surgical manipulation could have an important impact on long-term outcomes after lung cancer surgery. Also, our results suggested that it would be necessary to investigate the biological characteristics of CTCs in the future, such as analyzing surface ligand expression or performing DNA/RNA profiling for molecular markers. Surgical techniques the induced CTCs were observed in only four cases, and no trends in patient background, the characteristics of the CTCs, or the actual surgical procedures could be identified. This study suggests that surgical manipulation induces CTC release but did not specify how techniques varied across institutions. Future studies should provide details on surgical approaches (e.g., minimally invasive vs. open surgery) and their impact on CTC release. Nevertheless, the foundational data presented here could catalyze further research on CTCs and lung cancer prognosis, as well as the impact of surgical manipulation on lung cancer outcomes.
5. Conclusions
The presence of post-CTCs after PV dissection was associated with increased postoperative recurrence and significantly poorer RFS. However, no significant difference was observed in OS. Due to the small number of cases in this study, we were unable to identify specific effective surgical techniques. However, CTC monitoring may be a valuable tool in NSCLC management in the future.
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by A.K., Y.S. and N.S. The first draft of the manuscript was written by A.K. and all authors commented on previous versions of the manuscript and provided overall direction and guidance of the manuscript. All authors have read and agreed to the published version of the manuscript.
This multicenter prospective controlled study was ap-proved by the Institutional Ethics Review Board (Teikyo University Review Board 15-010) on 11 June 2015 and registered with the University Hospital Medical Information Network (UMIN000018602).
All participants provided written informed consent before study entry.
The raw data supporting the conclusions of this article will be made available by the authors on request.
The authors declare no conflicts of interest.
| ALT | Alanine aminotransferase |
| AST | Aspartate aminotransferase |
| CT | Computed tomography |
| CTCs | Circulating tumor cells |
| DNA | Deoxyribonucleic acid |
| ECOG | Eastern Cooperative Oncology Group |
| FEV1.0 | Volume per second |
| Hb | Hemoglobin |
| HBV | Hepatitis B virus |
| HCV | Hepatitis C virus |
| HIV | Human immunodeficiency virus |
| HR | Hazard ratio |
| NSCLC | Non-small cell lung cancer |
| OS | Overall survival |
| PaO2 | Partial pressure of arterial oxygen |
| PS | Performance Status |
| PV | Pulmonary vein |
| RFS | Recurrence-free survival |
| RNA | Ribonucleic acid |
| SaO2 | Arterial oxygen saturation |
| WBC | White blood cell |
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Enlarge this image.Figure 2. Recurrence-free survival curves for CTC positive convert group and pre-/post-CTCs-negative group (A), and for CTC positive convert group and pre-/post-CTCs-positive group (B).
Patients’ backgrounds.
| Pre-CTCs | Post-CTCs | ||||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | p-Value | Positive | Negative | p-Value | ||
| Gender | female | 5 (39) | 10 (62) | 0.27 | 7 (41) | 8 (67) | 0.26 |
| male | 8 (62) | 6 (38) | 10 (59) | 4 (33) | |||
| Age | ≤70 | 4 (31) | 9 (56) | 0.26 | 7 (41) | 6 (50) | 0.72 |
| >70 | 9 (69) | 7 (44) | 10 (59) | 6 (50) | |||
| Smoking index | <400 | 4 (31) | 10 (62) | 0.14 | 6 (35) | 8 (67) | 0.14 |
| ≥400 | 9 (69) | 6 (38) | 11 (65) | 4 (33) | |||
| Tumor diameter | ≤3 cm | 7 (54) | 7 (44) | 0.71 | 8 (47) | 6 (50) | 1.0 |
| >3 cm | 6 (46) | 9 (56) | 9 (53) | 6 (50) | |||
| Pathological stage | I | 4 (31) | 14 (87) | <0.01 | 7 (41) | 11 (92) | <0.01 |
| II, III, IV | 9 (69) | 2 (13) | 10 (59) | 1 (8) | |||
| Histology | adenocarcinoma | 10 (77) | 14 (87) | 0.63 | 13 (77) | 11 (92) | 0.37 |
| non-adenocarcinoma | 3 (23) | 2 (13) | 4 (23) | 1 (8) | |||
| Vascular invasion | negative | 5 (39) | 11 (69) | 0.14 | 7 (41) | 9 (75) | 0.13 |
| positive | 8 (61) | 5 (31) | 10 (59) | 3 (25) | |||
| Lymphatic invasion | negative | 6 (46) | 11 (69) | 0.27 | 8 (47) | 9 (75) | 0.25 |
| positive | 7 (54) | 5 (31) | 9 (53) | 3 (25) | |||
| Pleural invasion | negative | 7 (54) | 15 (94) | 0.026 | 11 (65) | 11 (92) | 0.19 |
| positive | 6 (46) | 1 (6) | 6 (35) | 1 (8) | |||
| Pulmonary metastasis | negative | 12 (92) | 16 (100) | 0.45 | 16 (94) | 12 (100) | 1.0 |
| positive | 1 (8) | 0 (0.0) | 1 (6) | 0 (0) | |||
| Total patients | 13 | 16 | 17 | 12 | |||
Relationship between pre- and post-CTCs.
| Post-CTCs | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Pre-CTCs | Positive | 13 | 0 | 13 |
| Negative | 4 | 12 | 16 | |
| Total | 17 | 12 | 29 | |
The number of local recurrences in patients with pre-/post-CTCs.
| Post-CTCs | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Pre-CTCs | Positive | 2/13 | 0/0 | 2/13 |
| Negative | 1/4 | 1/12 | 2/16 | |
| Total | 3/17 | 1/12 | 4/29 | |
The number of distant recurrences in patients with pre-/post-CTCs.
| Post-CTCs | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| Pre-CTCs | Positive | 7/13 | 0/0 | 7/13 |
| Negative | 1/4 | 1/12 | 2/16 | |
| Total | 8/17 | 1/12 | 9/29 | |
Relationship between CTCs status and recurrence site.
| Pre-CTCs | Post-CTCs | |||
|---|---|---|---|---|
| Recurrence Site | Positive | Negative | Positive | Negative |
| Local recurrence | ||||
| Ipsilateral lung | 2 | 1 | 2 | 1 |
| Bronchial stump | 1 | 0 | 1 | 0 |
| Dissemination/malignant pleural effusion | 0 | 0 | 0 | 0 |
| Hilar lymph node | 0 | 0 | 0 | 0 |
| Mediastinal lymph node | 2 | 2 | 3 | 1 |
| Distant metastasis | ||||
| Contralateral lung | 2 | 1 | 2 | 1 |
| Supraclavicular lymph node | 1 | 1 | 1 | 1 |
| Brain | 1 | 0 | 1 | 0 |
| Liver | 1 | 0 | 1 | 0 |
| Bone | 0 | 1 | 1 | 0 |
| Adrenal glands | 1 | 0 | 1 | 0 |
| Total patients | 13 | 16 | 17 | 12 |
Patient background of CTC positive convert group.
| Case | Gender | Age | Smoking | Tumor | Pathological | Histology | Vascular | Lymphatic |
|---|---|---|---|---|---|---|---|---|
| Index | Size (cm) | Stage | Invasion | Invasion | ||||
| 1 | M | 75 | 880 | 4 | IB | Sq | absent | absent |
| 2 | F | 63 | 0 | 3.2 | IIA | Ad | present | present |
| 3 | F | 59 | 0 | 2.1 | IA | Ad | present | present |
| 4 | M | 60 | 820 | 3.2 | IB | Ad | absent | absent |
Ad: adenocarcinoma; CTC: circulating tumor cell; Sq: squamous cell carcinoma.
Appendix A
Overall Survival
The 5-year overall survival rates for patients without or with pre-CTCs were 93.8% and 76.9%, respectively (p = 0.266;
The 5-year overall survival rates for the positive convert group and pre-/post-CTCs-negative patients were 75% and 100%, respectively (p = 0.078;
Enlarge this image.Figure A2. Overall survival curves for CTC positive convert group and pre-/post-CTCs-negative group (A), and for CTC positive convert group and post-CTCs-positive group (B).
References
1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin.; 2023; 73, pp. 17-48. [DOI: https://dx.doi.org/10.3322/caac.21763] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36633525]
2. Wu, Y.L.; Tsuboi, M.; He, J.; John, T.; Grohe, C.; Majem, M.; Goldman, J.W.; Laktionov, K.; Kim, S.W.; Kato, T. et al. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer. N. Engl. J. Med.; 2020; 383, pp. 1711-1723. [DOI: https://dx.doi.org/10.1056/NEJMoa2027071] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32955177]
3. Felip, E.; Altorki, N.; Zhou, C.; Csőszi, T.; Vynnychenko, I.; Goloborodko, O.; Luft, A.; Akopov, A.; Marti, A.M.; Kenmotsu, H. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): A ran-domised, multicentre, open-label, phase 3 trial. Lancet; 2021; 398, pp. 1344-1357. [DOI: https://dx.doi.org/10.1016/S0140-6736(21)02098-5]
4. O’Brien, M.; Paz-Ares, L.; Marreaud, S.; Dafni, U.; Oselin, K.; Havel, L.; Esteban, E.; Isla, D.; Marti, A.M.; Faehling, M. et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): An interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol.; 2022; 23, pp. 1274-1286. [DOI: https://dx.doi.org/10.1016/S1470-2045(22)00518-6]
5. Cristofanilli, M.; Hayes, D.F.; Budd, G.T.; Ellis, M.J.; Stopeck, A.; Reuben, J.M.; Doyle, G.V.; Matera, J.; Allard, W.J.; Miller, M.C. et al. Cir-culating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol.; 2005; 23, pp. 1420-1430. [DOI: https://dx.doi.org/10.1200/JCO.2005.08.140]
6. Guan, Y.; Xu, F.; Tian, J.; Gao, K.; Wan, Z.; Wang, Y.; Gao, M.; Wang, Z.; Chong, T. The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma. BMC Cancer; 2021; 21, 826. [DOI: https://dx.doi.org/10.1186/s12885-021-08463-7]
7. Torres, J.A.; Brito, A.B.C.; Silva, V.S.; Messias, I.M.; Braun, A.C.; Ruano, A.P.C.; Buim, M.E.C.; Carraro, D.M.; Chinen, L.T.D. CD47 Expression in Circulating Tumor Cells Circulating Tumor Microemboli from Non-Small Cell Lung Cancer Patients Is a Poor Prognosis Factor. Int. J. Mol. Sci.; 2023; 24, 11958. [DOI: https://dx.doi.org/10.3390/ijms241511958]
8. Tanaka, F.; Yoneda, K.; Kondo, N.; Hashimoto, M.; Takuwa, T.; Matsumoto, S.; Okumura, Y.; Rahman, S.; Tsubota, N.; Tsujimura, T. et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin. Cancer Res.; 2009; 15, pp. 6980-6986. [DOI: https://dx.doi.org/10.1158/1078-0432.CCR-09-1095]
9. Carlsson, A.; Nair, V.S.; Luttgen, M.S.; Keu, K.V.; Horng, G.; Vasanawala, M.; Kolatkar, A.; Jamali, M.; Iagaru, A.H.; Kuschner, W. et al. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J. Thorac. Oncol.; 2014; 9, pp. 1111-1119. [DOI: https://dx.doi.org/10.1097/JTO.0000000000000235]
10. Huang, J.; Xu, X.; Weng, Q.; Hong, H.; Guo, Z.; He, S.; Niu, J. Serial foodborne norovirus outbreaks associated with multiple gen-otypes. PLoS ONE; 2013; 8, e63327.
11. Barbirou, M.; Miller, A.; Manjunath, Y.; Ramirez, A.B.; Ericson, N.G.; Staveley-O’Carroll, K.F.; Mitchem, J.B.; Warren, W.C.; Chaudhuri, A.A.; Huang, Y. et al. Single Circulating-Tumor-Cell-Targeted Sequencing to Identify Somatic Variants in Liquid Biopsies in Non-Small-Cell Lung Cancer Patients. Curr. Issues Mol. Biol.; 2022; 44, pp. 750-763. [DOI: https://dx.doi.org/10.3390/cimb44020052]
12. Okumura, Y.; Tanaka, F.; Yoneda, K.; Hashimoto, M.; Takuwa, T.; Kondo, N.; Hasegawa, S. Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. Ann. Thorac. Surg.; 2009; 87, pp. 1669-1675. [DOI: https://dx.doi.org/10.1016/j.athoracsur.2009.03.073] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19463575]
13. Tarumi, S.; Gotoh, M.; Kasai, Y.; Matsuura, N.; Okuda, M.; Go, T.; Ishikawa, S.; Yokomise, H. Innovative method using circulating tumor cells for prediction of the effects of induction therapy on locally advanced non-small cell lung cancer. J. Cardiothorac. Surg.; 2013; 16, 175. [DOI: https://dx.doi.org/10.1186/1749-8090-8-175]
14. Matsutani, N.; Sawabata, N.; Yamaguchi, M.; Woo, T.; Kudo, Y.; Kawase, A.; Shiono, S.; Iinuma, H.; Morita, S.; Kawamura, M. Does lung cancer surgery cause circulating tumor cells?—A multicenter, prospective study. J. Thorac. Dis.; 2017; 9, pp. 2419-2426. [DOI: https://dx.doi.org/10.21037/jtd.2017.07.33]
15. Hashimoto, M.; Tanaka, F.; Yoneda, K.; Takuwa, T.; Matsumoto, S.; Okumura, Y.; Kondo, N.; Tsubota, N.; Tsujimura, T.; Tabata, C. et al. Significant increase in circulating tumour cells in pulmonary venous blood during surgical manipulation in patients with primary lung cancer. Interactive Cardiovasc. Thorac. Surg.; 2014; 18, pp. 775-783. [DOI: https://dx.doi.org/10.1093/icvts/ivu048]
16. Sawabata, N.; Funaki, S.; Hyakutake, T.; Shintani, Y.; Fujiwara, A.; Okumura, M. Perioperative circulating tumor cells in surgical patients with non-small cell lung cancer: Does surgical manipulation dislodge cancer cells thus allowing them to pass into the peripheral blood?. Surg. Today; 2016; 46, pp. 1402-1409. [DOI: https://dx.doi.org/10.1007/s00595-016-1318-4]
17. Jin, F.; Zhu, L.; Shao, J.; Yakoub, M.; Schmitt, L.; Reißfelder, C.; Loges, S.; Benner, A.; Schölch, S. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis. Eur. Respir. Rev.; 2022; 31, 220151. [DOI: https://dx.doi.org/10.1183/16000617.0151-2022]
18. Turnbull, R.B.; Kyle, K.; Watson, F.R.; Spratt, J. Cancer of the colon: The influence of the no-touch isolation technic on survival rates. Ann. Surg.; 1967; 166, pp. 420-427. [DOI: https://dx.doi.org/10.1097/00000658-196709000-00010]
19. Takii, Y.; Shimada, Y.; Moriya, Y.; Nakamura, K.; Katayama, H.; Kimura, A.; Shibata, T.; Fukuda, H. A randomized controlled trial of the conventional technique versus the no-touch isolation technique for primary tumor resection in patients with colorectal cancer: Japan Clinical Oncology Group Study JCOG1006. Jpn. J. Clin. Oncol.; 2014; 44, pp. 97-100. [DOI: https://dx.doi.org/10.1093/jjco/hyt156]
20. Refaely, Y.; Sadetzki, S.; Chetrit, A.; Simansky, D.A.; Paley, M.; Modan, B.; Yellin, A. The sequence of vessel interruption during lobectomy for non-small cell lung cancer: Is it indeed important?. J. Thorac. Cardiovasc. Surg.; 2003; 125, pp. 1313-1320. [DOI: https://dx.doi.org/10.1016/S0022-5223(03)00022-9]
21. Kurusu, Y.; Yamashita, J.; Hayashi, N.; Mita, S.; Fujino, N.; Ogawa, M. The sequence of vessel ligation affects tumor release into the circulation. J. Thorac. Cardiovasc. Surg.; 1998; 116, pp. 107-113. [DOI: https://dx.doi.org/10.1016/S0022-5223(98)70248-X] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9671904]
22. Song, P.P.; Zhang, W.; Zhang, B.; Liu, Q.; Du, J. Effects of different sequences of pulmonary artery and vein ligations during pulmonary lobectomy on blood micrometastasis of non-small cell lung cancer. Oncol. Lett.; 2013; 5, pp. 463-468. [DOI: https://dx.doi.org/10.3892/ol.2012.1022] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23420582]
23. Mastromarino, M.G.; Parini, S.; Azzolina, D.; Habib, S.; De Marni, M.L.; Luise, C.; Restelli, S.; Baietto, G.; Trisolini, E.; Massera, F. et al. Liquid Biopsy Detecting Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer: Preliminary Results of a Pilot Study. Biomedicines.; 2023; 11, 153. [DOI: https://dx.doi.org/10.3390/biomedicines11010153]
24. Soria, J.C.; Ohe, Y.; Vansteenkiste, J.; Reungwetwattana, T.; Chewaskulyong, B.; Lee, K.H.; Dechaphunkul, A.; Imamura, F.; Nogami, N.; Kurata, T. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N. Engl. J. Med.; 2018; 378, pp. 113-125. [DOI: https://dx.doi.org/10.1056/NEJMoa1713137]
25. Johnson, M.L.; Cho, B.C.; Luft, A.; Alatorre-Alexander, J.; Geater, S.L.; Laktionov, K.; Kim, S.W.; Ursol, G.; Hussein, M.; Lim, F.L. et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: The Phase III POSEIDON study. J. Clin. Oncol.; 2022; 41, pp. 1213-1227. [DOI: https://dx.doi.org/10.1200/JCO.22.00975]
26. Hibino, M.; Imamura, Y.; Shimoyama, R.; Fukui, T.; Fukai, R.; Iwase, A.; Tamura, Y.; Chihara, Y.; Okabe, T.; Uryu, K. et al. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. Target. Oncol.; 2024; 19, pp. 925-939. [DOI: https://dx.doi.org/10.1007/s11523-024-01094-5]
27. Cho, B.C.; Lu, S.; Felip, E.; Spira, A.I.; Girard, N.; Lee, J.S.; Lee, S.H.; Ostapenko, Y.; Danchaivijitr, P.; Liu, B. et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced, NSCLC. N. Engl. J. Med.; 2024; 391, pp. 1486-1498. [DOI: https://dx.doi.org/10.1056/NEJMoa2403614]
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
; Sekihara, Keigo 1
; Matsutani, Noriyuki 2 ; Yamaguchi, Masafumi 3 ; Kudo, Yujin 4
; Endo, Makoto 5
; Woo, Tetsukan 6 ; Saito, Yuichi 7
; Sawabata, Noriyoshi 8
1 First Department of Surgery, Hamamatsu University of Medicine, Hamamatsu 431-3192, Japan;
2 Department of Thoracic Surgery, Shin-Yurigaoka General Hospital, Kawasaki 215-0026, Japan;
3 Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka 811-1395, Japan;
4 Department of Surgery, Tokyo Medical University, Tokyo 160-8402, Japan;
5 Department of Thoracic Surgery, Yamagata Prefectural Central Hospital, Yamagata 990-2292, Japan;
6 Department of Surgery, Yokohama City University, Yokohama 232-0024, Japan;
7 Department of Surgery, Teikyo University School of Medicine, Tokyo 173-8605, Japan;
8 Department of Diagnostic Pathology, Nara Medical University, Kahihara 634-8521, Japan;